ENDV...IS GOLDEN !!! ENDV added to FDA SRO list as of

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
344
ENDV...IS GOLDEN !!!

ENDV added to FDA SRO list as of 10/5...

https://www.fda.gov/aboutfda/workingatfda/eth...079670.htm



Seaheck Wednesday, 11/08/17 11:07:14 AM



I'm not going anywhere. I'm here for the duration. I know WAY too much to bail. I've just got my hands tied on what I can say at this point. The closer we get to FDA trials, the more important what I "don't" say becomes. Forced to dial it back in here. Just know that things are in place to make this a massive investment for everyone here. It's a very structured and detailed flowchart of how things need to be done...and ARE being done. It's a slow methodical process, but everything is in place to happen in a very specific order for a certain reason. Trust the process. Today, tomorrow, the rest of this month, next month....NONE of it matters. I don't care if this dips below a penny or sails above a quarter. It's largely manipulated. That won't matter in a few months. Like those dumb infomercials...."Set it and forget it".
No sense to sweat the daily or weekly crap. Give it time and let it breathe. Believe me, we are golden. Quit stressing yourselves out....lol.



Seaheck Saturday, 10/07/17 12:28:49 PM

I think $ .50-$1.00 is a definite possibility with news. However, it's chicken scraps compared to where we will be 3-6 months after that. Because successful FDA trial results and then Nasdaq up-listing, its my opinion that by this time next year we will be easily over $5.00. That's a 70 bagger from here. It's also my opinion that in 3 years from now, we will be in the high double digit dollars minimum. I've consulted with a biotech analyst who is aware of everything going on here (also owns shares) who has assessed the patents and device and says its possible within a 3-5 year time frame we could be over $100 without even trying.
After multiple conversations about the business side of Endonovo, as well as the actual device's ability and patents we hold, my main reason for not posting here as much anymore is because he's convinced me to hold for a few years and not worry about the day to day, week to week stuff. He's right. He's been dead on with everything he's said and his only advice was to accumulate as much as you can afford to. This is a golden goose.
Have a great rest of the weekend!

Endonovo Therapeutics, Inc. (ENDV) Stock Research Links

ENDV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

MediaAlpha Set for Q3 2024 Financial Results Presentation

Updated Category News Views 77

MediaAlpha's Upcoming Financial Report Announcement MediaAlpha, Inc. (NYSE: MAX), based in Los Angeles, has exciting news for its investors and stakeholders. The company is gearing up to announce its financial results for the third quarter of 2024 on an upcoming Wednesday. This announcement will take place after the market closes, providing important insights into the...

Continue Reading
BigID Launches Innovative AI Data Access Control Solutions

Updated Category News Views 218

BigID Launches Innovative Solutions for AI Data Access Control Organizations are increasingly leveraging technology in ways that enhance workflows while prioritizing data security. BigID, a leader in the realm of data security and privacy, has introduced a groundbreaking method to prevent unauthorized access to sensitive information in Artificial Intelligence (AI)...

Continue Reading
Latigo Biotherapeutics Secures $150 Million to Innovate Pain Management

Updated Category News Views 442

Latigo Biotherapeutics Secures Major Funding for Pain Relief Advancement Latigo Biotherapeutics, a clinical-stage biotechnology firm dedicated to creating leading non-opioid pain management solutions, has officially closed a substantial $150 million in Series B financing. This funding round aims to push forward the development of their innovative Nav1.8 inhibitor...

Continue Reading
WisdomTree Moves Forward with UK Equity Income Shift

Updated Category News Views 119

WisdomTree's Strategic Shift in UK Equity Income In a significant move, the Directors of WisdomTree Issuer ICAV have officially announced plans to delist the WisdomTree UK Equity Income UCITS ETF. This decision comes as the company aims to merge its focus towards investing in UK Quality Dividend Growth strategies. The shares of this Sub-Fund will no longer be available...

Continue Reading
Avista Foundation's 2024 Grants: Supporting Community Initiatives

Updated Category News Views 384

Avista Foundation's Generous Grants in 2024 In its recent fourth-quarter granting cycle, the Avista Foundation has showcased its unwavering commitment to enhancing community welfare. The foundation distributed a remarkable total of $54,650 to 21 nonprofit organizations across various initiatives aimed at promoting environmental sustainability and enriching arts and...

Continue Reading